World Diabetes Market Analysis, 2009-2023

Questions: Discounts, Updates etc.

Pages: 121

Price (Single): £1499

Price (Departmental): £2999

Price (Company): £6999

Publication Date: 2009-02-10

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. As discussed in this new report - World Diabetes Market Analysis, 2009-2023 - The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing in health education, diagnosis and treatments for this chronic, debilitating - but controllable - disorder.

In 2007, the diabetes treatment market worldwide was worth over $25 billion, and had double-digit growth from the year before. Consequently, it is one of the largest sectors in the global healthcare industry. All segments of the diabetes therapy market have been expanding, but which will grow fastest in years to come? What are the key therapeutic and commercial trends to watch? How will the principal national markets perform from 2009 to 2023? What will happen to the current leading products/therapies? How does diabetes overlap with obesity? This report will answer those and other crucial questions about this large, increasingly important pharmaceutical market.

This report - World Diabetes Market Analysis, 2009-2023 - provides in-depth analysis of the markets for insulins, insulin analogues and oral anti-diabetics. This report also covers the new GLP-1 analogues – such as Byetta and liraglutide - as well as potentially revolutionary insulin delivery technologies. The study includes detailed sales forecasts for crucial products and market areas, providing the information you need to assess commercial aspects of the diabetes market fully. It covers both sales worldwide and for leading national markets, present and future. In addition to consultation with relevant experts - including interview transcripts - this original research involved a detailed study of policy documents, industrial reports and current developments, including R&D pipelines and line extensions. Importantly, the report authors applied techniques such as financial forecasting and analyses of market drivers and restraints. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that you will not find anywhere else.

Highlights of World Diabetes Market Analysis, 2009-2023 include:

 
Why you should buy this report:

 
This report predicts continuing expansion of the market for the whole range of diabetes treatments, driven by increasing disease incidence as well as improvements to diagnoses and treatment access, especially in developing countries. Successful participating companies will benefit as a result, gaining market prominence from high-value products. The healthcare industry cannot afford to ignore current developments in diabetes treatment, as shown in this report. Diabetes is arguably the greatest healthcare threat in developed countries and a rising scourge in countries such as China, India and Brazil. Pharmaceutical, biotechnological and diagnostics companies cannot afford to overlook this developing field, especially for innovative therapies.

Table of Contents

1 Executive Summary

  • 1.1 The Diabetes Market Trajectory
    • 1.1.1 Prediction for Total Diabetes Sales in 2023
    • 1.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for Pharmaceuticals is Growing
    • 1.1.3 Diabetes Care Works: The Market Will Expand
    • 1.1.4 Awareness, Advocacy and Government Spending Aimed at Diabetes are all Expanding
  • 1.2 Aims, Scope and Format of the Report
  • 1.3 Research Methodology

2 Introduction

  • 2.1 What is Diabetes Mellitus?
    • 2.1.1 Symptoms of Diabetes
    • 2.1.2 Type 1 Diabetes
    • 2.1.3 Type 2 Diabetes
    • 2.1.4 Gestational Diabetes
    • 2.1.5 Other types of Diabetes
    • 2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (IGT) and Metabolic Syndrome
  • 2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye and Nerve Damage
  • 2.3 Obesity: The Major Diabetes Risk Factor
  • 2.4 Other Risk Factors: Age, Genetics, Race
  • 2.5 Diagnosis: Guidelines are Subject to Change
  • 2.6 Prevalence: By All Measures, Diabetes Rates are Rising Epidemically
  • 2.7 The Economic Costs of Diabetes
  • 2.8 Treatments
    • 2.8.1 Insulin: A Therapeutic Mainstay
      • 2.8.1.1 Crucial Insulin Characteristics: Onset, Peak, and Duration Modifications
      • 2.8.1.2 Invasive Insulin Delivery Methods: Injections, Pumps, Insulin Jets
      • 2.8.1.3 Moving Away from Injections? Alternative Delivery Methods Under Development, and Set to Revolutionize the Market
    • 2.8.2 Other Medications
    • 2.8.3 More Novel Therapies? A New Discovery about How Insulin Works May Lead to New Drugs
  • 2.9 Diabetes Treatment Noncompliance Rates 25% to 90% Currently

3 World Diabetes Market, 2008-2023: Leading Drugs

  • 3.1 Market Forecast, 2008-2023
  • 3.2 Byetta Forecast
    • 3.2.1 Byetta’s Strengths
    • 3.2.2 Restraints on Byetta
  • 3.3 Oral Antidiabetics Forecast
  • 3.4 Actos Forecast
  • 3.5 Avandia Forecast
  • 3.6 Januvia Forecast
  • 3.7 Avandamet Forecast
  • 3.8 Human Insulin and Analogues Forecast
  • 3.9 Lantus Forecast
  • 3.10 Novorapid Forecast
  • 3.11 Humalog Forecast
  • 3.12 Novomix Forecast
  • 3.13 Actraphane HM Forecast
  • 3.14 Levemir Forecast
  • 3.15 Other Diabetes-related Drugs: Symlin and Kinedak
  • 3.16 Alternative Delivery Methods: The Possibilities to Watch
    • 3.16.1 Exubera: Cautionary Case Study
    • 3.16.2 Oral Delivery Technologies
    • 3.16.3 Transdermal Technologies

4 Leading Companies in Diabetes Treatment

  • 4.1 Novo Nordisk
    • 4.1.1 Insulin Plant to be Built in China
    • 4.1.2 FDA Delays Liraglutide Once-Daily
    • 4.1.3 Teaming up with Merrion for Oral Delivery Technologies
  • 4.2 Takeda
    • 4.2.1 May Seek Atherosclerosis Application for Actos
  • 4.3 sanofi-aventis
    • 4.3.1 Patent Infringement Case with Novo Nordisk and Eli Lilly
  • 4.4 Eli Lilly
    • 4.4.1 Eli Lilly’s Fortunes Closely Linked to Amylin’s Performance
  • 4.5 Amylin
    • 4.5.1 Amylin’s Future Tied to Byetta LAR
  • 4.6 Pipeline Developments
    • 4.6.1 Liraglutide
    • 4.6.2 Other GLP-1 Analogues
    • 4.6.3 DPP-4 Inhibitors
    • 4.6.4 Biguanides
    • 4.6.5 New Therapy Class: Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
    • 4.6.6 Insulin Pipeline: Mostly Focused On Delivery Methods
    • 4.6.7 Pipeline for Cures?

5 World Market Analysis by Region

  • 5.1 United States Forecast
  • 5.2 Europe Forecast
  • 5.3 Japan Forecast
  • 5.4 India Forecast
  • 5.5 China Forecast
  • 5.6 The Rest of the World

6 SWOT (Strengths, Weaknesses, Opportunities & Threats) Analysis

  • 6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Are Effective
    • 6.1.1 Diabetes is Chronic
    • 6.1.2 Younger Patients, More Comprehensive Diagnoses
    • 6.1.3 Prevention Inadequate
    • 6.1.4 Drugs Often Used in Combination
  • 6.2 Weaknesses
    • 6.2.1 Diagnostic Inadequacies
    • 6.2.2 Developing Countries Cannot Afford Many Newer Drugs
    • 6.2.3 Noncompliance Rates up to 65%
  • 6.3 Opportunities
    • 6.3.1 Expanding Markets: India and China
    • 6.3.2 Changing Guidelines for Diagnosing Diabetes
    • 6.3.3 Techniques for Increasing Patient Compliance
    • 6.3.4 Novel Drugs, Novel Delivery Methods
  • 6.4 Threats
    • 6.4.1 The Most-Significant Threat: Potential Changes in Drug Approval Guidelines
    • 6.4.2 Changing FDA Guidelines for New Drug Approvals
    • 6.4.3 Generic Erosion
    • 6.4.4 Vaccine to Prevent Type 1 Diabetes?
    • 6.4.5 Highly Publicised Diabetes Drugs Side Effects
  • 6.5 Interview with Fred Levine, M.D., Ph.D., Professor, Burnham Institute for Medical Research; Director, Sanford Children's Health Research Center
    • 6.5.1 Alternative Delivery Methods
    • 6.5.2 Cardiovascular Problems Associated with Oral Antidiabetics
    • 6.5.3 Obesity and Diabetes
    • 6.5.4 Byetta
    • 6.5.5 Stem Cell Therapy/Cure
  • 6.6 Interview with Björn Tyrberg, PhD., Associate Professor at Burnham Institute for Medical Research, Diabetes and Obesity Research Center
    • 6.6.1 Diet and Diabetes
    • 6.6.2 Link Between Obesity and Diabetes
    • 6.6.3 Byetta and liraglutide

7 Conclusions: Diabetes is a High Growth Market

  • 7.1 Diabetes Increasing Worldwide: High Prevalence and Incidence
  • 7.2 World Market Value by 2023
  • 7.3 How will Oral Antidiabetic and Insulin Sales Compare in the Future?

List of Tables

  • Table 2.1 Diabetes Numbers in Millions, by WHO Region
  • Table 2.2 Secondary Costs of Diabetes in the US
  • Table 2.3 Total Costs of Diabetes to Africa
  • Table 2.4 Diabetes World Market, 2007
  • Table 2.5 Insulin Types, by Onset Rate
  • Table 2.6 Alternative Delivery Methods in the Pipeline, by Type and Development Stage, 2008
  • Table 2.7 Antidiabetic Drugs by Class, 2008
  • Table 3.1 Diabetes Sales Forecast, 2008-2023
  • Table 3.2 Sales Forecasts for Oral Antidiabetics and Insulins, 2008-2023
  • Table 3.3 Byetta Sales Forecast, 2008-2023.
  • Table 3.4 Oral Antidiabetic Sales Forecast, 2008-2023
  • Table 3.5 Actos Sales Forecast, 2008-2023
  • Table 3.6 Avandia Sales Forecast, 2008-2023
  • Table 3.7 Januvia Sales Forecast, 2008-2023
  • Table 3.8 Avandamet Sales Forecast 2008-2023
  • Table 3.9 Insulin Sales Forecast 2008-2023
  • Table 3.10 Lantus Sales Forecast, 2008-2023
  • Table 3.11 Novorapid Sales Forecast, 2008-2023
  • Table 3.12 Humalog Sales Forecast, 2008-2023
  • Table 3.13 Novomix Sales Forecast, 2008-2023
  • Table 3.14 Actraphane HM Sales Forecast, 2008-2023
  • Table 3.15 Levemir Sales Forecast, 2008-2023
  • Table 3.16 Symlin Sales Forecast, 2008-2023
  • Table 3.17 Pipeline of Alternative Methods of Insulin Delivery, by Method and Development Stage, 2008
  • Table 4.1 Pipeline of Alternative Insulin Delivery Methods, 2008
  • Table 5.1 Sales and Market Share Forecasts, 2008-2023
  • Table 6.1 SWOT Table for Diabetes Therapies, 2008-2023

List of Figures

  • Figure 2.1 Rise in Diabetes Cases, by WHO Region
  • Figure 2.2 Secondary (Non-Medical) Costs of Diabetes in the US, 2007
  • Figure 2.3 Secondary Costs of Diabetes (minus direct medical costs), 2007
  • Figure 3.1 Total Diabetes Sales Forecast, 2008-2023
  • Figure 3.2 Diabetes Market, by Type and Market Share %, 2007
  • Figure 3.3 Sales Forecast for Oral Antidiabetics and Insulins, 2008-2023
  • Figure 3.4 Byetta Sales Forecast, 2008-2023
  • Figure 3.5 Oral Antidiabetic Sales Forecast, 2008-2023
  • Figure 3.6 Top Oral Antidiabetics, by Market Share, 2008
  • Figure 3.7 Actos Sales Forecast, 2008-2023
  • Figure 3.8 Avandia Sales Forecast 2008-2023
  • Figure 3.9 Januvia Sales Forecast, 2008-2023
  • Figure 3.10 Avandamet Sales Forecast, 2008-2023
  • Figure 3.11 Insulin Sales Forecast 2008-2023
  • Figure 3.12 Top-selling Insulins by Market Share
  • Figure 3.13 Lantus Sales Forecast, 2008-2023
  • Figure 3.14 Novorapid Sales Forecast, 2008-2023
  • Figure 3.15 Humalog Sales Forecast, 2008-2023
  • Figure 3.16 Novomix Sales Forecast, 2008-2023
  • Figure 3.17 Actraphane HM Sales Forecast, 2008-2023
  • Figure 3.18 Levemir Sales Forecast, 2008-2023
  • Figure 3.19 Symlin Sales Forecast, 2008-2023
  • Figure 4.1 Leading Companies by Market Share, 2007
  • Figure 5.1 Regional Sales Forecasts, 2008-2023
  • Figure 5.2 Market Share by Region, 2013
  • Figure 5.3 Market Share by Region, 2018
  • Figure 5.4 United States Sales Forecast, 2008-2023
  • Figure 5.5 European Sales Forecasts, 2008-2023
  • Figure 5.6 Japanese Sales Forecast, 2008-2023
  • Figure 5.7 Indian Sales Forecast, 2008-2023
  • Figure 5.8 Chinese Sales Forecast, 2008-2023
  • Figure 5.9 Rest of the World Sales Forecast, 2008-2023

Other users found this report page using the following search terms: diabetes GLP-1 Byetta liraglutide diabetes market 2009 chinese china world drugs share forecast analysis

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.